Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical enterprise specializing in the production and commercialization of medicinal products. Its operations span Hong Kong, the United States, Europe, Mainland China, and numerous other global markets. The company's business activities are structured into four primary segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and an 'Others' category. Within its product portfolio, key offerings include finished dose pharmaceuticals, notably enoxaparin sodium injection. Its API division supplies critical ingredients such as heparin sodium API and enoxaparin sodium API, alongside other compounds like pancreatin API. Beyond core products, Hepalink provides a suite of services encompassing research and development, manufacturing, quality management, and program management. This also extends to the creation and production of recombinant pharmaceutical products, essential non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical compounds. The group further diversifies its operations into areas such as property management, investment management and consulting, and equity and venture capital. It also engages in biopharmaceutical technology development and consulting, alongside the research, development, and production of biopharmaceuticals. Additional revenue streams include the production and sale of heparin sodium, various pharmaceutical-related service provisions, and the trading of medical and biopharmaceutical products. Established in 1998, the company is headquartered in Shenzhen, People's Republic of China. It adopted its current name, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., in February 2017, having previously operated as Shenzhen Hepalink Pharmaceutical Co.,Ltd.

CEO: Li Li - https://www.hepalink.com